Safety and efficacy of therapies for chylomicronemia.
Isabel ShamsudeenRobert A HegelePublished in: Expert review of clinical pharmacology (2022)
Emerging pharmacologic therapies for chylomicronemia show promise, particularly apo C-III antagonists. However, these treatments are still investigational. Further study of their efficacy and safety in patients with both rare FCS and more common multifactorial chylomicronemia is needed.